key: cord-0783320-nd2hfja7
authors: Hu, Jie; He, Chang-Long; Gao, Qing-Zhu; Zhang, Gui-Ji; Cao, Xiao-Xia; Long, Quan-Xin; Deng, Hai-Jun; Huang, Lu-Yi; Chen, Juan; Wang, Kai; Tang, Ni; Huang, Ai-Long
title: D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity
date: 2020-07-06
journal: bioRxiv
DOI: 10.1101/2020.06.20.161323
sha: e8339d5bf800131190a288f59bd81418d1c7804d
doc_id: 783320
cord_uid: nd2hfja7

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The spike (S) protein that mediates SARS-CoV-2 entry into host cells is a major target for vaccines and therapeutics. Thus, insights into its sequence variations are key to understanding the infection and antigenicity of SARS-CoV-2. A dominant mutational variant at position 614 of the S protein (aspartate to glycine, D614G mutation) was observed in the SARS-CoV-2 genome sequence obtained from the Nextstrain database. Using a pseudovirus-based assay, we identified that S-D614 and S-G614 protein pseudotyped viruses share a common receptor, human angiotensin-converting enzyme 2 (ACE2), which could be blocked by recombinant ACE2 with the fused Fc region of human IgG1. However, S-D614 and S-G614 protein demonstrated functional differences. First, S-G614 protein could be cleaved by serine protease elastase-2 more efficiently. Second, S-G614 pseudovirus infected 293T-ACE2 cells significantly more efficiently than did the S-D614 pseudovirus, especially in the presence of elastase-2. Third, an elastase inhibitor approved for clinical use blocked elastase-enhanced S-G614 pseudovirus infection. Moreover, 93% (65/70) convalescent sera from patients with COVID-19 could neutralize both S-D614 and S-G614 pseudoviruses with comparable efficiencies, but about 7% (5/70) convalescent sera showed reduced neutralizing activity against the S-G614 pseudovirus. These findings have important implications for SARS-CoV-2 transmission and immune interventions.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel 47 coronavirus reported in 2019 that caused the recent outbreak of coronavirus 48 disease 2019 (COVID-19) 1 . By July 4, 2020, the World Health Organization (WHO) 49 reported that 10.92 million people worldwide had been infected with SARS-CoV-2, 50 and that 523 000 individuals had died of COVID-19. This pandemic has had a 51 significant adverse impact on international, social, and economic activities. 52 Coronaviruses are enveloped, positive-stranded RNA viruses that contain the 53 largest known RNA genomes to date. The RNA genome of SARS-CoV-2 has been 54 rapidly sequenced to facilitate diagnostic testing, molecular epidemiologic source 55 tracking, and development of vaccines and therapeutic strategies 2 . The mutation 56 rate for RNA viruses is extremely high, which may contribute to their transmission 57 and virulence. The only significant variation in the SARS-CoV-2 spike (S) protein is 58 a non-synonymous D614G (aspartate (D) to glycine (G)) mutation 3 . Primary data 59 showed that S-G614 is a more pathogenic strain of SARS-CoV-2 with high 60 transmission efficiency 3 . However, whether the D614G mutation in the S protein 61 affects viral entry and infectivity in a cellular model is still unclear. The S protein of coronavirus, the major determinant of host and tissue tropism, is a 64 3 major target for vaccines, neutralizing antibodies, and viral entry inhibitors 4,5 . 65 Similar to SARS-CoV, the cellular receptor of SARS-CoV-2 is angiotensin- 66 converting enzyme 2 (ACE2); however, the SARS-CoV-2 S protein has a 10-to 67 20-fold higher affinity for ACE2 than the corresponding S protein of SARS-CoV 6,7 . 

D614G mutation of SARS-CoV-2 S protein was globally distributed 96 The S protein of SARS-CoV-2, which contains 1,273 amino acids, forms a trimeric 97 spike on the virion surface and plays an essential role in viral entry. We analyzed 98 the SARS-CoV-2 S protein amino acid sequence from viral genomic sequences in 99 the GISAID database. In line with prior reports, we found a globally distributed S 100 protein mutation, D614 to G614, which represented 64.6% of all the analyzed 101 sequences ( Fig. 1 and Table 1 ). Among the top 10 most abundant non-102 synonymous mutations observed in the S protein, the relative abundance of the 103 D614G mutant (the clade G) was the highest around the world, indicating that 104 G614 strain may be selectively advantageous. Since the S protein is critical to 105 coronavirus infection, we sought to explore the potential impact of the most 106 prevalent D614G mutation on the S protein structure, expression, and function.

Using the cryo-electron microscopy structure of S protein (PBD ID: 6ZGE) 108 5 determined by Wrobel et al. 10 , we analyzed the potential effects of the D614G 109 mutation. As shown in Fig. 1b , residue D614 is located at the C-terminal region of 110 the S1 domain, which directly associates with S2. On the one hand, residue D614 111 forms a hydrogen bond with backbone of G593 and a salt bridge with K854, and 112 then is capped by the folded 833-855 motif of chain B (Fig. 1c) . D614G mutation we observed that D614 is remarkably close to the N-linked glycosylation site N616 117 (Fig 1c) . Thus, the D614G mutation may enhance the fitness of SARS-CoV-2 by As the D614G mutation is proximal to the S1 cleavage domain, we predicted 123 potential cleavage sites of proteases in S protein variants using PROSPER 11 , and 124 identified a novel serine protease (elastase-2) cleavage site at residues 615-616 125 on the S1-S2 junction of the S-G614 protein (Fig. 2a Table S2 ). To evaluate the expression and cleavage of SARS-CoV-2 S protein in a 127 human cell line, the codon-optimized S protein-expressing plasmids (pS-D614 and 128 pS-G614) were transfected into HEK 293T cells. The immunoblot analysis of 129 whole cell lysates revealed that both S-D614 and S-G614 proteins showed two 130 6 major protein bands (unprocessed S and cleaved S1 subunit), when allowed to 131 react with the monoclonal antibody targeting the RBD on the SARS-CoV-2 S 132 protein (Fig. 2b) . However, the pS-G614-transfected cells showed a stronger S1 133 signal than pS-D614-transfected cells, indicating that the D614G mutation altered 134 the cleavability of the S protein by cellular proteases. Moreover, the elastase 135 inhibitor sivelestat sodium significantly decreased the S1 signal of S-D614 protein 136 (Fig. 2b) . These data indicate that the D614G mutation of SARS-CoV-2 S 137 facilitates its cleavage by host serine protease elastase-2. The coronavirus S 138 protein must be cleaved by host proteases to enable membrane fusion, which is 139 critical for viral entry. Next, we sought to explore the impact of D614G mutation on sodium than the S-D614 pseudovirus. 197 We also tested two other protease inhibitors, camostat mesylate and E-64d, which 198 block host TMPRSS2 and CatB/L, respectively. In 293T-ACE2 cells lacking 199 TMPRSS2, the serine protease inhibitor camostat mesylate did not inhibit S-D614 The serum from patient 1# failed to neutralize the S-G614 pseudovirus, even 225 though it neutralized about 30% of the S-D614 pseudovirus at a 1:1000 dilution.

Then, the inhibition curves and half-maximal inhibitory dose (ID50) of sera samples 227 from five convalescent patients and one healthy donor were analyzed. Sera from 228 patients 17# and 39#, which were able to neutralize both pseudoviruses to similar 229 degrees, showed similar ID50 values (Fig. 4b) . However, sera from patients 1#, 7#, 230 40#, 42# and 52# showed relative high neutralizing activity against the S-D614 231 pseudovirus with an ID50 ranging from 729 to 1524, but showed decreased 232 neutralizing activity against the S-G614 pseudovirus with an ID50 ranging from 216 233 to 367, indicating a 2.5-to 5.9-fold reduction in neutralizing titers (Fig. 4b) . These of the S-G614 protein, thereby enhancing viral entry into 293T-ACE2 cells (Fig. 5) . 247 We demonstrated the potential role of the elastase-2 inhibitor sivelestat in blocking In summary, we established a SARS-CoV-2 S protein-mediated pseudoviral entry 325 assay and explored the cellular entry of S-D614 and S-G614 pseudotyped viruses.

Our study provided evidence that the D614G mutation introduces an additional 327 elastase-2 cut site in the S protein, thereby promoting its cleavage and viral cell Table S1 ). All sera were tested positive using magnetic 

A pneumonia outbreak associated with a new coronavirus of probable 484 bat origin

Pharmacologic Treatments 486 for Coronavirus Disease 2019 (COVID-19): A Review

SARS-CoV-2 viral spike G614 mutation exhibits higher 489 case fatality rate

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is 491 Blocked by a Clinically Proven Protease Inhibitor

The spike protein of SARS-CoV -a target for vaccine and therapeutic 493 development

Cryo-EM structure of the 2019-nCoV spike in the prefusion 495 conformation

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike 497

Protease inhibitors targeting coronavirus and filovirus entry

Global Spread of SARS-CoV-2 Subtype with Spike Protein 501

Mutation D614G is Shaped by Human Genomic Variations that Regulate Expression of 502 TMPRSS2 and MX1 Genes

PROSPER: An Integrated Feature-Based Tool for Predicting Protease 508

Lentiviral vectors pseudotyped with a modified RD114 envelope 510 glycoprotein show increased stability in sera and augmented transduction of primary 511 lymphocytes and CD34+ cells derived from human and nonhuman primates

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant 514 ACE2-Ig

May Affect COVID-19 Vaccine Development and Antibody Treatment

Neutralizing antibodies against hepatitis C virus and the emergence 519 of neutralization escape mutant viruses

Patient-derived mutations impact pathogenicity of SARS-CoV-2

Protease-mediated 523 enhancement of severe acute respiratory syndrome coronavirus infection

Clinical effects of a neutrophil elastase inhibitor, sivelestat, in patients 526 24 with acute respiratory distress syndrome

Targeting potential drivers of COVID-19: Neutrophil extracellular traps

Neutrophil Elastase Inhibitors: A potential prophylactic treatment 530 option for SARS-CoV-2-induced respiratory complications?

Enhancing and Neutralizing Effects on Infection in Non-human Primates

A Novel Synonymous 535 Mutation of SARS-CoV-2: Is This Possible to Affect Their Antigenicity and 536 Immunogenicity? Vaccines

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 538 shedding and increases infectivity

Naturally mutated spike proteins of SARS-CoV-2 variants show 541 differential levels of cell entry

The D614G mutation in SARS-CoV-2 Spike 544 increases transduction of multiple human cell types

Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases 547 infectivity of the COVID-19 virus

An efficient method to make human monoclonal antibodies from 549 memory B cells: potent neutralization of SARS coronavirus

Vpr Is Required for Efficient Replication 552 of Human Immunodeficiency Virus Type-1 in Mononuclear Phagocytes

Antibody responses to SARS-CoV-2 in patients with COVID-19

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its 557 immune cross-reactivity with SARS-CoV

Comparison of 559 lentiviral vector titration methods

Cell entry mechanisms of SARS-CoV-2

 457 We would like to thank Prof. Cheguo Cai (Wuhan University, Wuhan, China) for 458 providing the pNL4-3.Luc.R-E-plasmid. We also grateful to Dr. Hongbing Jiang compare the S1 and S ratio, integrated density of S1/S was quantitatively 589 analyzed using ImageJ software. n = 3, ±SD. **P < 0.01.